Status:
NOT_YET_RECRUITING
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
Lead Sponsor:
Fudan University
Conditions:
Lung Cancer
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
This trial is a randomized, multicenter, open label phase II clinical study. The main objective is to evaluate the efficacy of three perioperative immunotherapy modalities (atezolizumab adjuvant thera...
Eligibility Criteria
Inclusion
- Patients who sign the informed consent form and are willing to complete the study according to the plan;
- Aged from 18 to 80 years old;
- ECOG equals 0 or 1;
- Not receiving lung cancer surgery before;
- Resectable cIB-IIIA tumors;
- Not receiving chemotherapy or radiotherapy before.
Exclusion
- Not cIB-IIIA tumors;
- Nodules not suitable for resection;
- Not lung adenocarcinoma diagnosed cytologically or pathologically;
- Receiving lung cancer surgery before;
- Receiving radiotherapy or chemotherapy.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2029
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06572722
Start Date
September 1 2024
End Date
September 1 2029
Last Update
August 27 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.